ARA-290

TheraTide USA

$50.99
Availability:
In Stock
Adding to cart… The item has been added

Product Overview

Compound: ARA‑290 (Cibinetide), non‑erythropoietic EPO‑derived peptide, 11‑amino acid helix B surface peptide

Form: Lyophilized powder, ≥95‑99 % purity, stored at ≤ –20 °C :contentReference[oaicite:1]{index=1}

For laboratory research only—NOT for human or veterinary use.

Batch-specific COA confirms purity ≥95–99 % (HPLC). COA available upon request—email providers@theratideusa.com.

  • Neuropathic pain relief: Binds tissue-protective innate repair receptor (IRR), inhibits TRPV1, and alleviates mechanical hypersensitivity in animal models :contentReference[oaicite:2]{index=2}.
  • Sarcoidosis & small-fiber neuropathy: Phase II RCT showed safety and reduced neuropathic pain, improved corneal nerve fiber density, physical function, and quality of life :contentReference[oaicite:3]{index=3}.
  • Diabetic neuropathy: In type 2 diabetics, daily subcutaneous dosing improved HbA1c, lipid profiles, pain symptoms, and corneal nerve growth :contentReference[oaicite:4]{index=4}.
  • Anti-inflammatory & tissue repair: Modulates macrophage activation, reduces IL‑6/IL‑12/TNF-α, promotes islet survival, neuroprotection, angiogenesis, and wound healing :contentReference[oaicite:5]{index=5}.
  • Depression & CNS effects: Reverses chronic-stress-induced depressive behavior and microglial activation in mice via anti‑inflammatory pathways :contentReference[oaicite:6]{index=6}.

Evidence spans preclinical and clinical studies; no adverse hematopoietic effects reported.

What is ARA‑290 used for?
Studied for neuropathic pain (e.g. sarcoidosis, diabetic neuropathy), depression, tissue repair, and metabolic support.

How does it work?
Activates tissue‑protective IRR (EPO receptor + CD131), blocks TRPV1 pain receptors, cytokine reduction, and reparative signaling.

What dosage was used clinically?
Typical dosing: 2 mg IV three times/week for neuropathy; 4 mg SC daily for diabetic neuropathy trials :contentReference[oaicite:7]{index=7}.

Any side effects?
Well-tolerated in trials with no major adverse effects or hematopoietic stimulation; mild injection-site reactions possible.

Storage & handling?
Store lyophilized ≤ –20 °C, protect from light and moisture, reconstitute before use.

For laboratory research only—not for human or veterinary use, nor as a dietary supplement.

Safety: Use appropriate lab equipment, follow storage protocols.

FDA Notice: These statements have not been evaluated by FDA. Not intended to diagnose, treat, cure, or prevent any disease.

All products offered by TheraTide USA are strictly intended for research and development purposes only.

None of the statements on this website have been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

TheraTide USA is a research chemical supplier. We are not a compounding pharmacy or a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.